A Review of Poloxamer 407-Induced Hyperlipidemia in In Vivo Studies

Abstract

Poloxamer-407, a surfactant and emulsifier commonly used in pharmaceutical formulations, has attracted attention as a potential contributor to increased lipid levels in the body based on in vivo research. A systematic review was conducted in January 2023 to examine the mechanisms by which poloxamer 407 contributes to the development of hyperlipidemia in in vivo studies published between 2010 and 2022, yielding 1240 results. Study selection was done using the PRISMA method. Manual screening, quality assessment, and data extraction from the search results were rigorously conducted in accordance with inclusion and exclusion criteria. Seventeen identified studies showed a correlation between the use of poloxamer 407 and a significant increase in blood lipid levels, creating conditions of hyperlipidemia. The significance of these findings lies in a deeper understanding of the potential side effects of poloxamer 407, especially in the context of human health. Its implications can guide further developments in the use of this compound or similar chemicals in pharmaceutical formulations. Therefore, this research provides a foundation for further studies that can detail the long-term impacts, underlying mechanisms, and possible mitigation strategies to manage side effects associated with the use of poloxamer 407.